Antibody Drug Conjugates Market Is Expected To Reach Revenue Of USD 51.2 Bn By 2033, at 15.8% CAGR: Dimension Market Research
05 sept. 2024 11h45 HE
|
Dimension Market Research
New York, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Overview The Global Antibody Drug Conjugates (ADCs) Market is projected to grow from USD 13.7 billion in 2024 to USD 51.2 billion by 2033, at a CAGR...
Shuttle Pharma Announces Issuance of U.S. Patent for Selective Histone Deacetylase Inhibitors for the Treatment of Human Disease
05 sept. 2024 09h00 HE
|
Shuttle Pharmaceuticals Holdings, Inc.
GAITHERSBURG, Md., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals, a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients...
BioNTech präsentiert auf dem ESMO-Kongress 2024 klinische Daten-Updates aus dem mRNA und immunmodulatorischen Onkologie-Portfolio
05 sept. 2024 07h15 HE
|
BioNTech SE
MAINZ, Deutschland, 05. September 2024 – BioNTech SE (Nasdaq: BNTX, „BioNTech“ oder „das Unternehmen“) wird auf dem diesjährigen Kongress der European Society for Molecular Oncology („ESMO“), der vom...
BioNTech to Present Clinical Data Updates Across mRNA and Immunomodulatory Oncology Portfolio at ESMO Congress 2024
05 sept. 2024 07h15 HE
|
BioNTech SE
MAINZ, Germany, September 05, 2024 – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will present clinical trial data for selected assets from its multi-platform oncology pipeline at the...
TransCode Therapeutics Awarded $2 Million NIH Grant to Support Clinical Evaluation of Lead Candidate
05 sept. 2024 07h00 HE
|
TransCode Therapeutics, Inc.
TransCode Therapeutics Awarded $2 Million NIH Grant to Support Clinical Evaluation of Lead Candidate
Shuttle Pharma Provides Second Quarter 2024 Corporate Update
04 sept. 2024 16h15 HE
|
Shuttle Pharmaceuticals Holdings, Inc.
GAITHERSBURG, Md., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma”), a discovery and development stage specialty pharmaceutical company...
Cross Keys Capital Advises Illinois CancerCare in Its Strategic Relationship with The US Oncology Network
04 sept. 2024 08h00 HE
|
Cross Keys Capital, LLC.
Fort Lauderdale, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Cross Keys Capital, a leading independent investment banking firm providing M&A advisory services to physician group practices and healthcare...
Claritas NucMed Technologies Secures Approval for its Subsidiary Claritas NucMed Tech Brazil to Forge Ahead the Commercialization of its Cutting-Edge Nuclear Medicine Software Solutions in Brazil
02 sept. 2024 10h00 HE
|
Claritas HealthTech Ltd
Claritas NucMed Technologies Secures Approval for its Subsidiary Claritas NucMed Tech Brazil to Forge Ahead the Commercialization of its leading SaMDs
AI in Oncology Market Size is Projected to Reach USD 7.7 billion by 2034, Growth at CAGR 16.8% | Report by Transparency Market Research, Inc.
02 sept. 2024 05h40 HE
|
Transparency Market Research
Wilmington, Delaware, United States, Transparency Market Research Inc. -, Sept. 02, 2024 (GLOBE NEWSWIRE) -- The global AI in oncology market (종양학 시장의 AI) is estimated to thrive at a CAGR of 16.8%...
Rakovina Therapeutics Announces 2024 Q2 Financial Results and Provides Corporate Update
30 août 2024 16h10 HE
|
Rakovina Therapeutics Inc
All dollar amounts reflected in Canadian dollars unless otherwise stated. VANCOUVER, British Columbia, Aug. 30, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV, the “Company”) a...